Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Tivozanib 0.89mg

Release date: 2024-07-10 13:51:14     Recommended: 132

04L1094_24 替沃扎尼 0.89mg 批文_00.jpg

Tivozanib is an oral VEGFR tyrosine kinase inhibitor (TKI), which is an effective and selective inhibitor of VEGFRs 1, 2, and 3. The FDA has approved Tivozanib/Fotivda for the treatment of adult recurrent or refractory advanced renal cell carcinoma (RCC) patients who have received two or more systemic therapies.

Company News

Research News

Drug news